-
NRP1 antagonism as a novel therapeutic target in nasal polyps of patients with chronic rhinosinusitis Allergy (IF 12.6) Pub Date : 2024-08-22 Roza Khalmuratova, Jae‐Sung Ryu, Ji Hyeon Hwang, Yi Sook Kim, Suha Lim, Ji‐Hun Mo, Jong‐Yeup Kim, Hyun‐Woo Shin
BackgroundNeuropilin‐1 (NRP1) is expressed on the surface epithelium of respiratory tract and immune cells, demonstrating its possible function in regulating the immune response in airway disease. However, its role in patient with chronic rhinosinusitis (CRS) remains unknown. This study aimed to elucidate the role of NRP1 in CRS with nasal polyps (CRSwNP).MethodsSinonasal biopsy specimens were immunohistochemically
-
Paediatric hospitalizations due to allergic reactions increasing in Finland and decreasing in Sweden Allergy (IF 12.6) Pub Date : 2024-08-22 Lasse Saarimäki, Sandra Ekström, Jennifer L. P. Protudjer, Heini Huhtala, Jussi Karjalainen, Inger Kull, Juho E. Kivistö
-
Evaluation of dupilumab on the disease burden in children and adolescents with atopic dermatitis: A population‐based cohort study Allergy (IF 12.6) Pub Date : 2024-08-22 Serena Yun‐Chen Tsai, Jonathan M. Gaffin, Elena B. Hawryluk, Hana B. Ruran, Lisa M. Bartnikas, Michiko K. Oyoshi, Lynda C. Schneider, Wanda Phipatanakul, Kevin Sheng‐Kai Ma
BackgroundDupilumab is the first and only biologic agent approved for the treatment of atopic dermatitis (AD) in pediatric patients aged from 6 months to 17 years. The study aimed to evaluate the impact of dupilumab on the occurrence of comorbidities in pediatric patients with AD.MethodsIn this population‐based cohort study, we utilized electronic health records from multiple healthcare organizations
-
An algorithm for the diagnosis and treatment of eosinophilic esophagitis in adults, 2024 update Allergy (IF 12.6) Pub Date : 2024-08-21 Marc Pfefferlé, Thomas Greuter
-
Multimodal profiling of biostabilized human skin modules reveals a coordinated ecosystem response to injected mRNA‐1273 COVID‐19 vaccine Allergy (IF 12.6) Pub Date : 2024-08-19 Manon Scholaert, Mathias Peries, Emilie Braun, Jeremy Martin, Nadine Serhan, Alexia Loste, Audrey Bruner, Lilian Basso, Benoît Chaput, Eric Merle, Pascal Descargues, Emeline Pagès, Nicolas Gaudenzio
BackgroundThe field of drug development is witnessing a remarkable surge in the development of innovative strategies. There is a need to develop technological platforms capable of generating human data prior to progressing to clinical trials.MethodsHere we introduce a new flexible solution designed for the comprehensive monitoring of the natural human skin ecosystem's response to immunogenic drugs
-
Higher levels of basal serum tryptase are associated with sensitization, FeNO, allergic morbidity, and lower control of allergic asthma in teenagers from the PARIS birth cohort Allergy (IF 12.6) Pub Date : 2024-08-19 Yannick Chantran, Simone Choi, Céline Roda, Pascale Nicaise‐Roland, Luc de Chaisemartin, Sylvie Chollet‐Martin, Michel Arock, Fanny Rancière, Isabelle Momas
-
Biomarkers for a less invasive strategy to predict children with eosinophilic esophagitis Allergy (IF 12.6) Pub Date : 2024-08-19 Helena Thulin, Ladan Mansouri, Maria Altman, Simon Kebede Merid, Joachim Lundahl, Caroline Nilsson, Jesper Säfholm
BackgroundNoninvasive biomarkers for diagnosing and monitoring eosinophilic esophagitis (EoE) are currently lacking. This study evaluates 20 biomarkers in serum and saliva, aiming to assess their diagnostic potential in pediatric EoE patients and healthy individuals.MethodsBlood and saliva from children undergoing upper endoscopy were analyzed for biomarkers, including absolute eosinophil count (AEC)
-
Recent patents in allergy and immunology: The interleukin‐2 receptor pathway agonist rezpegaldesleukin (REZPEG) for the rescue of regulatory T cells in chronic inflammatory and autoimmune diseases Allergy (IF 12.6) Pub Date : 2024-08-17 Christie Fanton, Jonathan Zalevsky
-
Indirect case‐matched comparison of anti‐IL4Rα versus anti‐IL5Rα on airway hyperresponsiveness Allergy (IF 12.6) Pub Date : 2024-08-17 Rory Chan, Kirsten Stewart, Chris RuiWen Kuo, Brian Lipworth
-
Type 2 memory B cells: The repository of allergic memory? Allergy (IF 12.6) Pub Date : 2024-08-16 Jesse Mulder, Alexandra R. Dvorscek, Zhoujie Ding
-
Proposed amendment to the nomenclature of allergic diseases and hypersensitivity reactions: Looking beyond the classic paradigms Allergy (IF 12.6) Pub Date : 2024-08-16 Lucyna Mastalerz
-
Assessment of sIgE to rLep d 2 for detecting Lepidoglyphus destructor sensitization Allergy (IF 12.6) Pub Date : 2024-08-11 Cristina Martin‐Garcia, Andrea Dionelly Murillo‐Casas, Milagros Lázaro‐Sastre, Miguel Estravís, Francisco Javier Muñoz‐Bellido, Elena Mazoteras‐Martinez, Ignacio Dávila
-
Species‐level, metagenomic and proteomic analysis of microbe‐immune interactions in severe asthma Allergy (IF 12.6) Pub Date : 2024-08-11 Maisha F. Jabeen, Nicholas D. Sanderson, Mariaenrica Tinè, Gillian Donachie, Clair Barber, Adnan Azim, Laurie C. K. Lau, Thomas Brown, Ian D. Pavord, Anoop Chauhan, Paul Klenerman, Teresa L. Street, Emanuele Marchi, Peter H. Howarth, Timothy S. C. Hinks
BackgroundThe airway microbiome in severe asthma has not been characterised at species‐level by metagenomic sequencing, nor have the relationships between specific species and mucosal immune responses in ‘type‐2 low’, neutrophilic asthma been defined. We performed an integrated species‐level metagenomic data with inflammatory mediators to characterise prevalence of dominant potentially pathogenic organisms
-
Alopecia areata exhibits cutaneous and systemic OX40 activation across atopic backgrounds Allergy (IF 12.6) Pub Date : 2024-08-08 Madeline Kim, Ester Del Duca, Dante Dahabreh, Daniel Lozano‐Ojalvo, Britta Carroll, Meredith Manson, Swaroop Bose, Digpal Gour, Monali NandyMazumdar, Ying Liu, Mitchelle Yu Ekey, Amira Chowdhury, Michael Angelov, Benjamin Ungar, Yeriel Estrada, Emma Guttman‐Yassky
BackgroundAlopecia areata (AA) is a chronic, nonscarring hair‐loss disorder associated with significant quality‐of‐life impairment and limited treatment options. AA has been recently linked to atopy and shown to exhibit both Th1‐ and Th2‐driven inflammation. However, a comprehensive molecular and cellular characterization across blood and scalp compartments in both atopic and nonatopic patients is
-
Mepolizumab depletes inflammatory but preserves homeostatic eosinophils in severe asthma Allergy (IF 12.6) Pub Date : 2024-08-08 Michael Fricker, John Harrington, Sarah A. Hiles, Peter G. Gibson
BackgroundEosinophils are key therapeutic targets in severe asthma that are suppressed by IL5 (mepolizumab) and IL5 receptor (benralizumab) blockade. The effect of IL5 pathway biologics on recently described homeostatic (hEOs) and inflammatory (iEOs) eosinophil subsets is unknown. We aimed to determine the relative impact of mepolizumab and benralizumab treatment on eosinophil subset and phenotype
-
Impact of a drug allergy education course for non‐specialists: Findings from ADAPT—A randomized crossover trial Allergy (IF 12.6) Pub Date : 2024-08-07 Michaela Lucas, Hugo W. F. Mak, Jasmine T. Y. Lee, Rishabh Kulkarni, Sophia S. C. Chan, Philip H. Li
BackgroundThe consequences of drug allergy remain a global health concern. Drug allergy is often a neglected topic and many non‐specialists lack sufficient knowledge or confidence in evaluating or managing this common condition. Evidence‐based interventions to better equip non‐specialists to tackle drug allergy are needed. The aim of the study is to evaluate the effectiveness of an intensive educational
-
Real‐world data show sustained therapeutic effects of dupilumab in chronic rhinosinusitis with nasal polyps (CRSwNP) over 3 years Allergy (IF 12.6) Pub Date : 2024-08-07 Patrick Huber, Ulrike Förster‐Ruhrmann, Heidi Olze, Sven Becker, Friederike Bärhold, Mandy Cuevas, Nadine Gunder, Jan Hagemann, Christoph Matthias, Ludger Klimek, Moritz Gröger
BackgroundChronic rhinosinusitis with nasal polyps (CRSwNP) is a prevalent chronic inflammatory condition affecting the nose and paranasal sinuses, posing a significant socio‐economic impact with substantial challenges in management. Biologics targeting type 2 inflammation such as dupilumab, have emerged as promising options. This study addresses a critical knowledge gap by comprehensively evaluating
-
Transcriptomic profiles of well‐differentiated airway epithelial cells in response to environmental triggers of asthma exacerbation Allergy (IF 12.6) Pub Date : 2024-08-07 Antonella Marrocco, Jennifer A. Mitchel, Margaret Parker, Maureen McGill, Robert P. Chase, Scott T. Weiss, Diane R. Gold, Peter J. Castaldi, Elliot Israel, Jin‐Ah Park, Joanne E. Sordillo
-
Navigating the evolving landscape of atopic dermatitis: Challenges and future opportunities: The 4th Davos declaration Allergy (IF 12.6) Pub Date : 2024-08-05 Claudia Traidl‐Hoffmann, Jamie Afghani, Cezmi Akdis, Mübecel Akdis, Handan Aydin, Katja Bärenfaller, Heidrun Behrendt, Thomas Bieber, Paul Bigliardi, Mei Bigliardi‐Qi, Charlotte Menné Bonefeld, Stefanie Bösch, Marie Charlotte Brüggen, Sebastian Diemert, Hans‐Werner Duchna, Martina Fähndrich, Danielle Fehr, Marc Fellmann, Remo Frei, Lena H. Garvey, Raschid Gharbo, Mehmet Gökkaya, Karin Grando, Carole
The 4th Davos Declaration was developed during the Global Allergy Forum in Davos which aimed to elevate the care of patients with atopic dermatitis (AD) by uniting experts and stakeholders. The forum addressed the high prevalence of AD, with a strategic focus on advancing research, treatment, and management to meet the evolving challenges in the field. This multidisciplinary forum brought together
-
IgE glycosylation and impact on structure and function: A systematic review Allergy (IF 12.6) Pub Date : 2024-08-05 Alexandra J. McCraw, Lais C. G. F. Palhares, Jenifer L. Hendel, Richard A. Gardner, Aida Santaolalla, Silvia Crescioli, James McDonnell, Mieke Van Hemelrijck, Alicia Chenoweth, Daniel I. R. Spencer, Gerd K. Wagner, Sophia N. Karagiannis
The impact of human IgE glycosylation on structure, function and disease mechanisms is not fully elucidated, and heterogeneity in different studies renders drawing conclusions challenging. Previous reviews discussed IgE glycosylation focusing on specific topics such as health versus disease, FcεR binding or impact on function. We present the first systematic review of human IgE glycosylation conducted
-
Key factors that influence quality of life in patients with IgE‐mediated food allergy vary by age Allergy (IF 12.6) Pub Date : 2024-08-03 Stephanie A. Kubala, Fernanda D. Young, Viviane Callier, Marjohn M. Rasooly, Caeden Dempsey, Erica Brittain, Pamela A. Frischmeyer‐Guerrerio
BackgroundWhile food allergy (FA) can be fatal, the greatest public health impact of FA arguably lies in its detrimental effect on quality of life (FAQOL). Understanding the factors that contribute to FAQOL at different ages is essential to develop personalized interventions that will improve FAQOL.ObjectiveTo determine the most influential factors that impact FAQOL across ages in well‐phenotyped participants
-
Children with elevated wheat IgG4 antibody titer in autism spectrum disorder: Clinical presentation and findings associated with gut microbiota Allergy (IF 12.6) Pub Date : 2024-08-02 Yixiao Tian, Xin Luo, Jianxiong Chen, Huiteng Rong, Huinuo Wang, Bing Li, Jing Li, Xin You
-
Proton pump inhibitor effect on esophageal protein signature of eosinophilic esophagitis, prediction, and evaluation of treatment response Allergy (IF 12.6) Pub Date : 2024-08-02 Francisca Molina‐Jiménez, Lola Ugalde‐Triviño, Laura Arias‐González, Elisa Armenteros, Carlos Relaño‐Rupérez, Sergio Casabona, José Andrés Moreno‐Monteagudo, María Teresa Pérez‐Fernández, Verónica Martín‐Domínguez, Jennifer Fernández‐Pacheco, Emilio José Laserna‐Mendieta, Patricia Muñoz‐Hernández, Jorge García‐Martínez, Javier Muñoz, Alfredo J. Lucendo, Cecilio Santander, Pedro Majano
BackgroundRecently, we have identified a dysregulated protein signature in the esophageal epithelium of eosinophilic esophagitis (EoE) patients including proteins associated with inflammation and epithelial barrier function; however, the effect of proton pump inhibitor (PPI) treatment on this signature is unknown. Herein, we used a proteomic approach to investigate: (1) whether PPI treatment alters
-
Therapeutic relevance of eosinophilic inflammation and airway viral interactions in severe asthma Allergy (IF 12.6) Pub Date : 2024-08-01 Hitasha Rupani, William W. Busse, Peter H. Howarth, Philip G. Bardin, Ian M. Adcock, Satoshi Konno, David J. Jackson
The role of eosinophils in airway inflammation and asthma pathogenesis is well established, with raised eosinophil counts in blood and sputum associated with increased disease severity and risk of asthma exacerbation. Conversely, there is also preliminary evidence suggesting antiviral properties of eosinophils in the airways. These dual roles for eosinophils are particularly pertinent as respiratory
-
Trajectories of egg sensitization in childhood: Two birth cohorts in Asia and Europe Allergy (IF 12.6) Pub Date : 2024-08-01 Toshinori Nakamura, Taiji Nakano, Angela Simpson, Michihiro Kono, John A. Curtin, Tomoko Kobayashi, Clare S. Murray, Masashi Akiyama, Masahiro Imanishi, Masayuki Mikuriya, Adnan Custovic, Naoki Shimojo
BackgroundHen's egg exposure through impaired skin barrier is considered a major mechanism of sensitization to eggs. However, the impact of filaggrin (FLG) gene loss‐of‐function mutations on the natural history of egg sensitization lacks consensus among studies.ObjectiveTo evaluate the association between the natural course of egg sensitization and FLG mutations.MethodsWe used Japanese and the UK birth
-
-
Vitamin D‐FUT2 interaction and risk of lower respiratory tract infections in childhood Allergy (IF 12.6) Pub Date : 2024-07-30 Nicklas Brustad, Jakob Stokholm, Klaus Bønnelykke, Bo L. Chawes
-
IL‐10‐modulated dendritic cells from birch pollen‐ and hazelnut‐allergic patients facilitate Treg‐mediated allergen‐specific and cross‐reactive tolerance Allergy (IF 12.6) Pub Date : 2024-07-29 Patricia Vanessa Heinl, Edith Graulich, Benno Weigmann, Andrea Wangorsch, Robert Ose, Iris Bellinghausen, Rahul Khatri, Verena K. Raker, Stephan Scheurer, Stefan Vieths, Joachim Saloga, Kerstin Steinbrink
BackgroundApproximately 70% of individuals allergic to birch pollen (Bet v 1.01 [Bet]) develop a secondary food allergy (e.g., hazelnut: Cor a 1.04 [Cor]), due to allergen cross‐reactivity. However, standard immunotherapy for type I allergies often does not improve the food allergy sufficiently. We analyzed the allergen‐specific and cross‐reactive suppressive capacity of primary human regulatory T
-
Systemic reactions to house dust mite subcutaneous immunotherapy in patients with allergic rhinitis and/or asthma: A real‐life, multi‐center study Allergy (IF 12.6) Pub Date : 2024-07-26 Qingxiu Xu, Jiaxin Jia, Hang Lin, Dan Liang, Hao Chen, Yin Wang, Xiang Gao, Wang Liao, Guohua Chen, Lihong Yang, Qianlan Zhou, Jun Bai, Zhihai Xie, Lishen Shan, Rongfei Zhu
-
Anaplastic lymphoma kinase as a new therapeutic target in inflammatory itch Allergy (IF 12.6) Pub Date : 2024-07-26 Tiphaine Voisin, Elodie Labit, Nicolas Gaudenzio, Lilian Basso
-
An algorithm for the diagnosis and treatment of chronic inducible Urticaria, 2024 update Allergy (IF 12.6) Pub Date : 2024-07-26 Marcus Maurer, Hanna Bonnekoh, Eva Grekowitz, Lea Kiefer, Melba Munoz, Manuel P. Pereira, Dorothea Terhorst‐Molawi
-
Characterization of omalizumab updosing patterns and predictive factors in chronic spontaneous urticaria: A prospective multicentric observational study Allergy (IF 12.6) Pub Date : 2024-07-26 Guillaume Pierrard, Claire Bernier, Aurélie Du‐Thanh, Corina Bara, Angèle Soria, Florence Castelain, Isabelle Boccon‐Gibod, Florence Hacard, Juliette Delaunay, Laurence De Montjoye, Delphine Staumont‐Salle, Frédéric Dezoteux
BackgroundLimited information is available on the use of omalizumab (OMA) updosing since its introduction as a second‐line therapy in chronic spontaneous urticaria (CSU) in 2014. Practical guidelines from health authorities are lacking, and the specific characteristics of patients requiring higher doses remain unknown. Our objectives were to characterize the patterns of OMA updosing (defined as changes
-
Anti‐TNF therapy impairs both short‐ and long‐term IgG responses after repeated vaccination Allergy (IF 12.6) Pub Date : 2024-07-25 Jana Sophia Buhre, Tamas Pongracz, Ulf Martin Geisen, Mareike Schubert, Wenjun Wang, Jan Nouta, Maureen Obara, Selina Lehrian, Johann Rahmöller, Janina Petry, Florian Tran, Stefan Schreiber, Melike Sümbül, Dennis Berner, Sascha Gerdes, Jan Schirmer, Ann Carolin Longardt, Paula Hoff, Ulrich Kalinke, Ralf J. Ludwig, Yannic C. Bartsch, Bimba F. Hoyer, Manfred Wuhrer, Marc Ehlers
BackgroundRecently, it has been questioned whether vaccination of patients with inflammatory (auto)immune diseases under anti‐tumor necrosis factor (TNF) treatment leads to impaired vaccine‐induced immune responses and protection against breakthrough infections. However, the effects of TNF blockade on short‐ and long‐term immune responses after repeated vaccination remain unclear. Vaccination studies
-
Mast cell responses in a mouse model of food allergy are regulated via a ST2/IL‐4 axis Allergy (IF 12.6) Pub Date : 2024-07-25 Saurav Ranjitkar, Dylan Krajewski, Caitlin Tedeschi, Nicole Maldonado Perez, Nathan Jordan, Kelly Gregory, Sallie S. Schneider, Clinton B. Mathias
-
Disease modification in chronic spontaneous urticaria Allergy (IF 12.6) Pub Date : 2024-07-24 Marcus Maurer, Pavel Kolkhir, Manuel P. Pereira, Frank Siebenhaar, Ellen Witte‐Händel, Karl‐Christian Bergmann, Hanna Bonnekoh, Thomas Buttgereit, Joachim W. Fluhr, Stefan Frischbutter, Eva Maria Grekowitz, Leonie Herzog, Lea Alice Kiefer, Karoline Krause, Markus Magerl, Melba Muñoz, Sophia Neisinger, Nicole Nojarov, Samantha Prins, Polina Pyatilova, Aisté Ramanauskaité, Jörg Scheffel, Dorothea Terhorst‐Molawi
Chronic spontaneous urticaria (CSU) is a debilitating, inflammatory skin condition characterized by infiltrating immune cells. Available treatments are limited to improving the signs and symptoms. There is an unmet need to develop therapies that target disease‐driving pathways upstream of mast cell activation to inhibit or delay the progression of CSU and associated comorbidities. Here, we aim to define
-
Characterising the allergic fungal rhinosinusitis microenvironment using full‐length 16S rRNA gene amplicon sequencing and fungal ITS sequencing Allergy (IF 12.6) Pub Date : 2024-07-24 J. T. Connell, G. Bouras, K. Yeo, K. Fenix, C. Cooksley, A. Bassiouni, S. Vreugde, P. J. Wormald, A. J. Psaltis
IntroductionAllergic fungal rhinosinusitis (AFRS) is a severe phenotype of chronic rhinosinusitis with nasal polyposis (CRSwNP), characterised by localised and exaggerated type 2 inflammation. While fungal antigenic stimulation of unregulated Th2‐mediated inflammation is the core pathophysiological mechanism, the direct and synergistic role of bacteria in disease modification is a pervasive hypothesis
-
From allergy to oncology: Targeting IL‐4 to boost cancer immunotherapy Allergy (IF 12.6) Pub Date : 2024-07-24 Filippo Consonni, Antonio Corsello, Francesco Pegoraro
-
Clinical efficacy of tezepelumab in pre‐selected non‐type 2 asthma patients Allergy (IF 12.6) Pub Date : 2024-07-22 T. C. (Timothy) Chin‐See‐Chong, J. P. M. (Johanna) van der Valk, J. A. (Janice) Layhadi, M. H. (Mohamed) Shamji, J. H. (Jasper) Kappen
-
Granulocytes and mast cells in AllergoOncology—Bridging allergy to cancer: An EAACI position paper Allergy (IF 12.6) Pub Date : 2024-07-22 Mariona Pascal, Heather J. Bax, Christoph Bergmann, Rodolfo Bianchini, Mariana Castells, Jitesh Chauhan, Leticia De las Vecillas, Karin Hartmann, Elena Izquierdo Álvarez, Uta Jappe, Teodorikez‐Wilfox Jimenez‐Rodriguez, Edward Knol, Francesca Levi‐Schaffer, Cristobalina Mayorga, Aurélie Poli, Frank Redegeld, Alexandra F. Santos, Erika Jensen‐Jarolim, Sophia N. Karagiannis
Derived from the myeloid lineage, granulocytes, including basophils, eosinophils, and neutrophils, along with mast cells, play important, often disparate, roles across the allergic disease spectrum. While these cells and their mediators are commonly associated with allergic inflammation, they also exhibit several functions either promoting or restricting tumor growth. In this Position Paper we discuss
-
Effects of dupilumab on quality of life burden in refractory type 2 high unified airway disease Allergy (IF 12.6) Pub Date : 2024-07-21 Kirsten E. Stewart, Chris RuiWen Kuo, Rory Chan, Brian J. Lipworth
-
Elucidating allergic reaction mechanisms in response to SARS‐CoV‐2 mRNA vaccination in adults Allergy (IF 12.6) Pub Date : 2024-07-21 Mihir M. Shah, Janice A. Layhadi, Dennis E. Hourcade, William T. Fulton, Tiak Ju Tan, Diane Dunham, Iris Chang, Monica S. Vel, Andrea Fernandes, Alexandra S. Lee, James Liu, Prabhu S. Arunachalam, Stephen J. Galli, Scott D. Boyd, Bali Pulendran, Mark M. Davis, Ruth O'Hara, Helen Park, Lynne M. Mitchell, Antonina Akk, Alexander Patterson, Maya R. Jerath, Jennifer M. Monroy, Zhen Ren, Peggy L. Kendall
BackgroundDuring the COVID‐19 pandemic, novel nanoparticle‐based mRNA vaccines were developed. A small number of individuals developed allergic reactions to these vaccines although the mechanisms remain undefined.MethodsTo understand COVID‐19 vaccine‐mediated allergic reactions, we enrolled 19 participants who developed allergic events within 2 h of vaccination and 13 controls, nonreactors. Using standard
-
Mesenchymal stromal cells effectively limit house dust mite extract‐induced mixed granulocytic lung inflammation Allergy (IF 12.6) Pub Date : 2024-07-19 Marlena Tynecka, Adrian Janucik, Agnieszka Tarasik, Arkadiusz Zbikowski, Magdalena Niemira, Agnieszka Kulczynska‐Przybik, Anna Zeller, Nino Stocker, Joanna Reszec‐Gielazyn, Barbara Mroczko, Adam Kretowski, Cezmi A. Akdis, Milena Sokolowska, Marcin Moniuszko, Andrzej Eljaszewicz
-
In chronic spontaneous urticaria, increased Galectin‐9 expression on basophils and eosinophils is linked to high disease activity, endotype‐specific markers, and response to omalizumab treatment Allergy (IF 12.6) Pub Date : 2024-07-18 Jiang Ji, Minhui Tang, Yue Zhao, Chuqiao Zhang, Yu Shen, Bin Zhou, Cuiping Liu, Marcus Maurer, Qingqing Jiao
BackgroundGalectin‐9 (Gal‐9) has been implicated in allergic and autoimmune diseases, but its role and relevance in chronic spontaneous urticaria (CSU) are unclear.ObjectivesTo characterize the role and relevance of Gal‐9 in the pathogenesis of CSU.MethodsWe assessed 60 CSU patients for their expression of Gal‐9 on circulating eosinophils and basophils as well as T cell expression of the Gal‐9 receptor
-
Epithelial barrier theory in the context of nutrition and environmental exposure in athletes Allergy (IF 12.6) Pub Date : 2024-07-16 Walter Kistler, Michael Villiger, Beat Villiger, Duygu Yazici, Yagiz Pat, Yasutaka Mitamura, Sena Ardicli, Stephen Skolnick, Raja Dhir, Mübeccel Akdis, Kari Nadeau, Ismail Ogulur, Cezmi A. Akdis
Exposure to toxic substances, introduced into our daily lives during industrialization and modernization, can disrupt the epithelial barriers in the skin, respiratory, and gastrointestinal systems, leading to microbial dysbiosis and inflammation. Athletes and physically active individuals are at increased risk of exposure to agents that damage the epithelial barriers and microbiome, and their extreme
-
Allergenic potency of various foods of mammalian origin in patients with α‐Gal syndrome Allergy (IF 12.6) Pub Date : 2024-07-15 Marija Perusko, Jeanette Grundström, Maria Eldh, Annika Reinhardt, Verena Fuhrmann, Meltem Düzakin, Carl Hamsten, Maria Starkhammar, Danijela Apostolovic, Marianne van Hage
BackgroundThe α‐Gal syndrome (AGS) is an emerging allergy to mammalian food caused by IgE‐mediated reactions to the carbohydrate galactose‐α‐1,3‐galactose (α‐Gal). Mammalian food sources contain α‐Gal, but the amount differs. The objective of this study was to investigate the allergenic potency of various foods of mammalian origin among AGS patients.MethodsTwenty‐six AGS patients were included. Food
-
Differential decline of SARS‐CoV‐2‐specific antibody levels, innate and adaptive immune cells, and shift of Th1/inflammatory to Th2 serum cytokine levels long after first COVID‐19 Allergy (IF 12.6) Pub Date : 2024-07-14 Bernhard Kratzer, Pia Gattinger, Doris Trapin, Paul Ettel, Ulrike Körmöczi, Arno Rottal, Robert B. Stieger, Al Nasar Ahmed Sehgal, Melanie Feichter, Kristina Borochova, Inna Tulaeva, Katharina Grabmeier‐Pfistershammer, Peter A. Tauber, Thomas Perkmann, Ingrid Fae, Sabine Wenda, Michael Kundi, Gottfried F. Fischer, Rudolf Valenta, Winfried F. Pickl
BackgroundSARS‐CoV‐2 has triggered a pandemic and contributes to long‐lasting morbidity. Several studies have investigated immediate cellular and humoral immune responses during acute infection. However, little is known about long‐term effects of COVID‐19 on the immune system.MethodsWe performed a longitudinal investigation of cellular and humoral immune parameters in 106 non‐vaccinated subjects ten
-
Pyroptosis, gasdermins and allergic diseases Allergy (IF 12.6) Pub Date : 2024-07-14 Ronald Allan Panganiban, Kari C. Nadeau, Quan Lu
Pyroptosis is an inflammatory form of programmed cell death that is distinct from necrosis and apoptosis. Pyroptosis is primarily mediated by the gasdermin family of proteins (GSDMA‐E and PVJK), which, when activated by proteolytic cleavage, form pores in the plasma membrane, leading to cell death. While much of the past research on pyroptosis has focused on its role in cancer, metabolic disorders
-
Evolution of pathologic B‐cell subsets and serum environment‐specific sIgEs in patients with atopic dermatitis and controls, from infancy to adulthood Allergy (IF 12.6) Pub Date : 2024-07-14 Tali Czarnowicki, Eden David, Kazuhiko Yamamura, Joseph Han, Helen He, Ana B. Pavel, Jacob Glickman, Taylor Erickson, Yeriel Estrada, James G. Krueger, Stephanie M. Rangel, Amy S. Paller, Emma Guttman‐Yassky
BackgroundWhile B‐cells have historically been implicated in allergy development, a growing body of evidence supports their role in atopic dermatitis (AD). B‐cell differentiation across ages in AD, and its relation to disease severity scores, has not been well defined.ObjectiveTo compare the frequency of B‐cell subsets in blood of 0–5, 6–11, 12–17, and ≥18 years old patients with AD versus age‐matched
-
Alpine altitude climate treatment improves asthma control, irrespective of biologics use Allergy (IF 12.6) Pub Date : 2024-07-12 Karin B. Fieten, Marieke T. Drijver‐Messelink, Rolf Wolters, Bart Hilvering, Susanne J.H. Vijverberg, Els J. Weersink
-
Children with eosinophilic esophagitis non‐responsive to combination therapy have distinct esophageal transcriptomic and microbiome profile Allergy (IF 12.6) Pub Date : 2024-07-12 Girish Hiremath, Yash Choksi, Hernan Correa, Justin Jacobse, Suman R. Das, Siyuan Ma, Jeremy A. Goettel, Seesandra V. Rajagopala
BackgroundA combination of proton‐pump inhibitors (PPI) and topical steroids (TS) is used to treat children with eosinophilic esophagitis (EoE). However, a subset of children do not respond to this combination therapy. We aimed to identify the esophageal transcriptional, cell composition, and microbial differences between the non‐responders (EoE‐PPI‐TSnr; n = 7) and responders (EoE‐PPI‐TSr; n = 7)
-
Forecasting daily total pollen concentrations on a global scale Allergy (IF 12.6) Pub Date : 2024-07-12 László Makra, Luca Coviello, Andrea Gobbi, Giuseppe Jurman, Cesare Furlanello, Mauro Brunato, Lewis H. Ziska, Jeremy J. Hess, Athanasios Damialis, Maria Pilar Plaza Garcia, Gábor Tusnády, Lilit Czibolya, István Ihász, Áron József Deák, Edit Mikó, Zita Dorner, Susan K. Harry, Nicolas Bruffaerts, Ann Packeu, Annika Saarto, Linnea Toiviainen, Maria Louna‐Korteniemi, Sanna Pätsi, Michel Thibaudon, Gilles
BackgroundThere is evidence that global anthropogenic climate change may be impacting floral phenology and the temporal and spatial characteristics of aero‐allergenic pollen. Given the extent of current and future climate uncertainty, there is a need to strengthen predictive pollen forecasts.MethodsThe study aims to use CatBoost (CB) and deep learning (DL) models for predicting the daily total pollen
-
Allergen‐specific B cell responses in oral immunotherapy‐induced desensitization, remission, and natural outgrowth in cow's milk allergy Allergy (IF 12.6) Pub Date : 2024-07-11 Pattraporn Satitsuksanoa, Willem van de Veen, Ge Tan, Juan‐Felipe Lopez, Oliver Wirz, Kirstin Jansen, Milena Sokolowska, David Mirer, Anna Globinska, Tadech Boonpiyathad, Stephan R. Schneider, Elena Barletta, Hergen Spits, Iris Chang, Huseyn Babayev, İlhan Tahralı, Gunnur Deniz, Esra Özek Yücel, Ayca Kıykım, Scott D. Boyd, Cezmi A. Akdis, Kari Nadeau, Mübeccel Akdis
BackgroundAntigen‐specific memory B cells play a key role in the induction of desensitization and remission to food allergens in oral immunotherapy and in the development of natural tolerance (NT). Here, we characterized milk allergen Bos d 9‐specific B cells in oral allergen‐specific immunotherapy (OIT) and in children spontaneously outgrowing cow's milk allergy (CMA) due to NT.MethodsSamples from
-
Childhood infections, asthma and allergy trajectories, and chronic rhinosinusitis in middle age: A prospective cohort study across six decades Allergy (IF 12.6) Pub Date : 2024-07-11 Jennifer L. Perret, N. Sabrina Idrose, E. Haydn Walters, Dinh S. Bui, Adrian J. Lowe, Caroline J. Lodge, Anne R. Fernandez, Vivian Yao, Iain Feather, Xiao‐Wen Zeng, Bruce R. Thompson, Bircan Erbas, Michael J. Abramson, Shyamali C. Dharmage
IntroductionEvidence on the early life risk factors of adult CRS, and the history of asthma and allergies across the life course, is limited.AimTo investigate relationships between respiratory infective/allergic conditions in childhood, and asthma and allergies across the life course and CRS in middle age.MethodsData were from the population‐based Tasmanian Longitudinal Health Study (TAHS) cohort,
-
-
Anti‐rubella IgG serum levels predict risk for SARS‐CoV‐2 breakthrough infections Allergy (IF 12.6) Pub Date : 2024-07-09 Moritz M. Hollstein, Sascha Dierks, Michael P. Schön, Uwe Groß, Karin Thiele, Andreas Leha, Andreas E. Zautner, Andreas Fischer, Luise Erpenbeck, Moritz Schnelle
-
Reaction severity and peach threshold amount during oral challenge in nonspecific lipid transfer protein allergy Allergy (IF 12.6) Pub Date : 2024-07-09 Natalia Pérez‐Sánchez, Carmen Rondón, José Antonio Cañas, Rocío Sáenz de Santa María‐García, Julia Rodríguez, Marta Andugar‐Moreno, Cristobalina Mayorga, María José Torres, Francisca Gómez
-
Person‐centred care in allergen immunotherapy in a digital era Allergy (IF 12.6) Pub Date : 2024-07-09 Chew Lip Ng, De Yun Wang
-
Incidence and risk factors of cutaneous reactions to the first COVID‐19 booster vaccine Allergy (IF 12.6) Pub Date : 2024-07-09 Liam R. Smith, Ruchi J. Shah, Andrew J. King, Erica S. Shenoy, Adam B. Landman, Dean M. Hashimoto, Kimberly Blumenthal
-
An algorithm for the diagnosis and treatment of Hymenoptera venom allergy, 2024 update Allergy (IF 12.6) Pub Date : 2024-07-09 Gunter J. Sturm, Lisa Arzt‐Gradwohl
-
A recent patent in allergy & immunology: Biomarkers on allergen‐specific memory B cells to predict allergen immunotherapy outcome Allergy (IF 12.6) Pub Date : 2024-07-09 Menno C. van Zelm, Robyn E. O'Hehir, Craig I. McKenzie